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Isolated limb perfusion (ILP) is a limb salvage procedure for inoperable 
limb melanoma with local in transit metastasis, and in selected cases for 
sarcomas as well. It allows to avoid amputation, improve dramatically 
local conditions and quality of life but does not increase global survival. 
The advanced concept applied in the CHUV is the combination of local 
chemotherapy with Tumour Necrosis Factor (TNF) and hyperthermia to 
increase local drug uptake and improve local complete response. 
The ILP concept was developed by Creech, Ryan and Krementz in 19571. 
The idea was to perfuse local chemotherapy in a limb only, controlled by a 
tourniquet, with the main benefit of up to 10 times the maximum systemic 
tolerated chemotherapy doses, applied selectively to the limb without syste-
mic toxicity2. Many experiences and reviews have assessed the indications 
for melanoma and soft tissue sarcoma patients2. Interestingly, ILP was deve-
loped in Europe mainly, where the adjunct of TNF demonstrated a significant 
improvement in efficacy2. Despite many trials, TNF is still not FDA approved 
nor licensed in USA. 
Due to high systemic toxicity, TNF management makes strict conditions in 
order to assess the risk of systemic contamination mandatory, and is to per-
formed with a special accredited multidisciplinary team including Surgical 
Oncology, Nuclear Medicine, Medical Oncology, sarcoma and melanoma 
teams as well as an Intensive Care Unit. There are currently about 40 certified 
centres performing ILPs in Europe, two in Switzerland: CHUV in Lausanne 
since 1990 and more recently the University Hospital of Basel.
Several agents have been tested for ILP but melphalan is more commonly 
used. As single agent complete response (CR) is observed in about 50% 
melanoma patient with in transit limb metastases. Other agents like cisplatin 
and carboplatin have been applied but with higher local toxicity3, 4. Another 
derived technique was promoted by Thompson as Isolated Limb Infusion 
(ILI), with canulation through a controlateral intravascular route5. Fotemustin 
ILI after melphalan failure, was used in combination with systemic dacar-
bazine6. ILI is however limited to the lower limb and is not suitable to treat 
disease up to the groin. Recombinant Tumour Necrosis Factor (TNFa-1a, 
Tasonerminum) is a proapoptotic molecule for angiogenic endothelial cells of 
tumours7, which induces vasoplegia increasing drug uptake and which has 
synergy with Interferon gamma. Combination of melphalan with TNF incre-
ases CR up to 80-90%. Mild hyperthermia (40-41,5°C) is an additional factor 
to further increase local effect of melphalan. For sarcoma however, even if 
the association of melphalan with TNF is more effective than melphalan alo-
ne, CR is observed in 18% only8. 
Indications
Melanoma: The major indication is in transit metastases in melanoma 
patients where surgical resection is not feasible (fig. 1). A large multicentric 
randomized trial showed that prophylactic ILP following curative melanoma 
surgery could increase disease-free interval for loco-regional recurrence, but 
offer no significant impact on distant metastases and overall survival9. 
Non-resectable sarcomas: in soft tissue sarcoma limb-sparing surgery 
combined with external beam radiotherapy is feasible in up to 90% of pati-
ents10. Amputation does not improve survival, which is conditioned by size, 
grade and distant metastasis. ILP in this setting may be used as neo-adju-
vant therapy in order to perform a safe RO resection (fig. 2) or as exclusive 
palliative therapy11. 
Miscellaneous: squamous cell carcinoma and Merkel cell carcinoma12, des-
moid tumours13 and T-cell lymphoma14. 
Quality of life is obviously improved in tumour patients who can preserve 
their diseased limb15 , even if survival will not be prolonged by the ILP pro-
cedure. For this reason, limited distant metastases is not a contraindication 
for ILP. After ILP about 50% melanoma patients will recur. A second (and 
third) ILP can be performed with more than 60% CR16. Sequential scheduled 
melphalan ILP cumulates toxicity and is no more indicated. Age (>75) is not a 
contraindication: results are similar when compared with younger patients17.
Surgical technique for ILP
Patients are selected in multidisciplinary sarcoma or melanoma tumour 
boards. For upper limbs, vascular canulation is either subclavian or axillary 
and for lower limbs is either iliac or femoral. A simultaneous radical lymph 
node dissection is performed according to the vascular access. In melanoma 
patients pelvic metastatic lymph node dissection may be beneficial, when 
distant disease is not observed18. In sarcomas lymph node metastasis is rare: 
overall less than 5%19, 20 but related to histology (0,6% in undifferentiated 
sarcoma and around 20% in epithelioid sarcoma and rhabdomyosarcoma20). 
Metastatic lymph nodes have a poor prognosis when associated with distant 
metastatic disease21. 
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The procedure is performed on a limb isolated by a tourniquet (applied at 
the root of the limb) with extaracorporeal circulation. Potential systemic leaks 
in the system are checked with technecium 99 labelled albumin. We use 
fluorescein and Wood lamp to assess the skin territory perfused. Sequential 
chemotherapy with TNF (plus INF for melanoma) and melphalan are perfused 
as soon as hyperthermia > 38,0°C is reached. In some centre compartmental 
tissue pressure is monitored22 in order to detect compartmental syndrome. 
The entire procedure lasts about 5 hours. After one or two days of recovery 
in the intensive care unit the patient starts rehabilitation. Mean hospital stay 
is 7-10 days, but full recovery necessitates assistance and physiotherapy up 
to 3 months.
Results and toxicity
For unresectable melanoma the main endpoint is limb salvage and quality of 
life. Because ILP remains a regional therapy overall survival will not be pro-
longed2. ILP as exclusive treatment has 45-90% CR and a limb salvage rate 
up to 96%2, 23. In a series of 15 nonmelanoma skin tumours CR was obtained 
in 60% and limb saved in 80% of patients12. In sarcoma patients the objec-
tive response (CR + partial) is 81-91% with limb salvage rate of 81-90%2, 8. In 
the CHUV in Lausanne we performed 255 ILP in 211 patients between 1990 
and 2008. One ILP was performed once in 170 patients, twice in 38 and three 
times in 3 patients. Indications were in transit metastatic melanoma in 197, 
soft tissue sarcoma in 55, epidermoid carcinoma in 2 and Merkel cell tumour 
in one patient. Sarcoma patients were recently reviewed24 showing 25% CR, 
resection of tumour remnants was performed in 65% and final amputation 
rate was 24% with a mean follow-up of 38,9 months (4-159).
Severe toxicity may include vasoplegia and shock, myelotoxicity, heart, liver, 
kidney and lung failures. Limb toxicity includes skin burns, rhabdomyolisis, 
neurotoxicity and rare septic necrosis leading to amputation. Post-ILP Crea-
tinine Kinase monitoring may help detecting patients who may need fascio-
tomy, which is rarely necessary and performed25.
Conclusion
ILP is a challenging therapy to be performed in specialized centres with multi-
disciplinary teams. As a loco-regional therapy ILP is important as limb sparing 
surgery for melanoma and soft tissue sarcoma patients. Other chemotherapy 
agents and specially the optimal TNF doses26 are still in investigation.
Fig. 1. Melanoma patient. A 71 year-old woman was operated on for a Breslow 
3mm melanoma of the right ankle followed 10 months later by a first ILP (TNF, INF 
and melphalan) for rapidly growing in transit metastases. Eight out of 13 ilio-ob-
turator lymph nodes were metastatic. No objective response was observed. Me-
tastatic skin nodules progressed with local infection. A second ILP was planned 
10 months later with one-week preparation (antibiotics and local disinfection). A. 
One week before ILP. B. One week after ILP. C. Five weeks after ILP.
Fig. 2. Sarcoma patient. A 75 year-old man presented with a deep bulky sarcoma 
of the right thigh in the posterior compartment adjacent to the neuro-vascular 
bundle. Because of the risk of an R2 resection, a neoadjuvant ILP was planned. 
Ilio-obturator dissection revealed no lymph node metastasis (0/11). MRI (T1) at 2 
and 4 months showed about 80% necrosis. Recovery was slow due to severe lym-
phoedema. Five months later a wide safe RO resection sparing sciatic nerve de-
monstrated a liposarcoma with 100% necrosis in the undifferentiated component 
and living tissues in the grade I liposarcoma area. Recovery was uneventful.
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